Overview
- The facility at 1401 Severn Street in the Gaslight Square complex is slated for a two-phase buildout through 2031.
- Operations will be run by Nature Cell America with a focus on knee osteoarthritis and Alzheimer’s research, clinical trials, and manufacturing of investigational products.
- The company states a goal of producing up to one million doses per year of its JointStem stem cell injection.
- Maryland’s commerce department is working to approve a $4 million conditional loan, and the Baltimore Development Corporation has proposed a $400,000 conditional loan with permitting assistance.
- Nature Cell purchased the West Baltimore property this fall for $10 million, according to the deal’s broker, after citing the state’s stem cell fund and life sciences workforce as key draws.